New research shows that the asthma drug benralizumab failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD, a history of frequent moderate and/or severe exacerbations, and eosinophilic inflammation.
Click here for original story, Benralizumab not effective reducing exacerbations in moderate to very severe COPD
Source: ScienceDaily